4.4 Article

Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer

Related references

Note: Only part of the references are listed.
Review Oncology

Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review

Hannah C. Timmins et al.

Summary: Metabolic syndrome and associated conditions have been identified as potential risk factors for chemotherapy-induced peripheral neurotoxicity (CIPN). Obesity and low physical activity may contribute to the development of CIPN. Further research is needed to explore CIPN risk factors and determine if lifestyle changes can improve long-term outcomes for cancer survivors.

JOURNAL OF CANCER SURVIVORSHIP (2023)

Article Medicine, General & Internal

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas

Martina Catalano et al.

Summary: The combination of nab-paclitaxel and gemcitabine has shown greater efficacy in treating metastatic pancreatic cancer patients compared to gemcitabine alone but with a higher risk of chemotherapy-induced peripheral neuropathy (CINP). Patients experiencing CINP may have a more favorable outcome, with higher disease control rates and prolonged median survival than those without neuropathy.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Clinical Neurology

Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients

Jetter Robertson et al.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2018)

Review Clinical Neurology

Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics

Andreas A. Argyriou et al.

NATURE REVIEWS NEUROLOGY (2017)

Review Biotechnology & Applied Microbiology

Microtubule-binding agents: a dynamic field of cancer therapeutics

Charles Dumontet et al.

NATURE REVIEWS DRUG DISCOVERY (2010)